New Oral GLP-1 Medication Shows Promise for Diabetes and Weight Management

A recent clinical trial demonstrated that an investigational oral GLP-1 receptor agonist, elecoglipron, effectively reduced HbA1c levels and supported weight loss in adults with type 2 diabetes. These positive phase 2b results suggest a potential new treatment option that could improve patient access to GLP-1 therapies.